A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C

This study is ongoing, but not recruiting participants.
Information provided by Vertex Pharmaceuticals Incorporated

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Hepatitis C
2		Additional conditions recognized in this trial
			Hepatitis
3		More general conditions related to this trial
			Digestive System Diseases
			Flaviviridae Infections
			Hepatitis, Viral, Human
			Liver Diseases
			RNA Virus Infections
			Virus Diseases
4		Interventions listed in this trial
			Telaprevir
			Ribavirin
			Peg-interferon Alfa-2a
5		Additional drug interventions recognized in this trial
			Interferon Alfa-2a
			Interferon-alpha
			Interferons
			Peginterferon alfa-2a
6		More general drug interventions related to this trial
			Angiogenesis Inhibitors
			Angiogenesis Modulating Agents
			Anti-Infective Agents
			Antimetabolites
			Antineoplastic Agents
			Antiviral Agents
			Growth Inhibitors
			Growth Substances
			Immunologic Factors
			Molecular Mechanisms of Pharmacological Action
			Pharmacologic Actions
			Physiological Effects of Drugs
			Therapeutic Uses
7		Sponsors listed in this trial
			Vertex Pharmaceuticals Incorporated